The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Reversal of experimental pulmonary hypertension by PDGF inhibition
Open accessAbstract
Progression of pulmonary hypertension is associated with increased proliferation and migration of pulmonary vascular smooth muscle cells. PDGF is a potent mitogen and involved in this process. We now report that the PDGF receptor antagonist STI571 (imatinib) reversed advanced pulmonary vascular disease in 2 animal models of pulmonary hypertension. In rats with monocrotaline-induced pulmonary hypertension, therapy with daily administration of STI571 was started 28 days after induction of the disease. A 2-week treatment resulted in 100% survival, compared with only 50% in sham-treated rats. The changes in RV pressure, measured continuously by telemetry, and right heart hypertrophy were reversed to near-normal levels. STI571 prevented phosphorylation of the PDGF receptor and suppressed activation of downstream signaling pathways. Similar results were obtained in chronically hypoxic mice, which were treated with STI571 after full establishment of pulmonary hypertension. Moreover, expression of the PDGF receptor was found to be significantly increased in lung tissue from pulmonary arterial hypertension patients compared with healthy donor lung tissue. We conclude that STI571 reverses vascular remodeling and cor pulmonale in severe experimental pulmonary hypertension regardless of the initiating stimulus. This regimen offers a unique novel approach for antire-modeling therapy in progressed pulmonary hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Ushio-Fukai, M., Griendling, K. K., Becker, P. L., Hilenski, L., Halleran, S., & Alexander, R. W. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.4.489 · Cited by 283
RetractedBuchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2558 · Cited by 270
RetractedPROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
The mitogen-activated protein kinase signal transduction pathway
Davis, R. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82362-6 · Cited by 2,139
Inhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Cellular and molecular pathobiology of pulmonary arterial hypertension
Humbert, M., Morrell, N. W., Archer, S. L., Stenmark, K. R., MacLean, M. R., Lang, I. M., Christman, B. W., Weir, E. K., Eickelberg, O., Voelkel, N. F., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.029 · Cited by 1,576
Cited by
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Molecular pathogenesis of pulmonary arterial hypertension
Rabinovitch, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33452 · Cited by 880
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Mechanisms of disease: pulmonary arterial hypertension
Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.87 · Cited by 800
Self-citationStenmark, K. R., Meyrick, B., Galie, N., Mooi, W. J., & McMurtry, I. F. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00217.2009 · Cited by 774
Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
Hassoun, P. M., Mouthon, L., Barberà, J. A., Eddahibi, S., Flores, S. C., Grimminger, F., Jones, P. L., Maitland, M. L., Michelakis, E. D., Morrell, N. W., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.006 · Cited by 710
Self-citationPulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Molecular pathogenesis of pulmonary arterial hypertension
Rabinovitch, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60658 · Cited by 653
Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension
Tuder, R. M., Archer, S. L., Dorfmüller, P., Erzurum, S. C., Guignabert, C., Michelakis, E., Rabinovitch, M., Schermuly, R., Stenmark, K. R., & Morrell, N. W. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.025 · Cited by 585
Self-citationHoeper, M. M., Barst, R. J., Bourge, R. C., Feldman, J., Frost, A. E., Galié, N., Gómez-Sánchez, M. A., Grimminger, F., Grünig, E., Hassoun, P. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000765 · Cited by 574
Pediatric Pulmonary Hypertension
Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M. F., Bonnet, D., Fleming, T. R., Haworth, S. G., Raj, J. U., Rosenzweig, E. B., Schulze Neick, I., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.028 · Cited by 536
Archer, S. L., Weir, E. K., & Wilkins, M. R. (2010) · Circulation · doi:10.1161/circulationaha.108.847707 · Cited by 485
Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension
Perros, F., Montani, D., Dorfmüller, P., Durand-Gasselin, I., Tcherakian, C., Le Pavec, J., Mazmanian, M., Fadel, E., Mussot, S., Mercier, O., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-1037oc · Cited by 472
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Moslehi, J. J., & Deininger, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4718 · Cited by 443
Pathology of Pulmonary Hypertension
Tuder, R. M., Stacher, E., Robinson, J., Kumar, R., & Graham, B. B. (2013) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.08.009 · Cited by 439
The monocrotaline model of pulmonary hypertension in perspective
Gomez-Arroyo, J. G., Farkas, L., Alhussaini, A. A., Farkas, D., Kraskauskas, D., Voelkel, N. F., & Bogaard, H. J. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00212.2011 · Cited by 424
Inflammation in Pulmonary Arterial Hypertension
Price, L. C., Wort, S. J., Perros, F., Dorfmüller, P., Huertas, A., Montani, D., Cohen-Kaminsky, S., & Humbert, M. (2012) · Chest · doi:10.1378/chest.11-0793 · Cited by 403
Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy
Ghofrani, H. A., Morrell, N. W., Hoeper, M. M., Olschewski, H., Peacock, A. J., Barst, R. J., Shapiro, S., Golpon, H., Toshner, M., Grimminger, F., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0123oc · Cited by 384
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Hansmann, G., de Jesus Perez, V. A., Alastalo, T.-P., Alvira, C. M., Guignabert, C., Bekker, J. M., Schellong, S., Urashima, T., Wang, L., Morrell, N. W., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32503 · Cited by 367
Hansmann, G., Wagner, R. A., Schellong, S., de Jesus Perez, V. A., Urashima, T., Wang, L., Sheikh, A. Y., Suen, R. S., Stewart, D. J., & Rabinovitch, M. (2007) · Circulation · doi:10.1161/circulationaha.106.663120 · Cited by 366
Bonnet, S., Rochefort, G., Sutendra, G., Archer, S. L., Haromy, A., Webster, L., Hashimoto, K., Bonnet, S. N., & Michelakis, E. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610467104 · Cited by 364
Force, T., & Kolaja, K. L. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3252 · Cited by 363
Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice
Seimetz, M., Parajuli, N., Pichl, A., Veit, F., Kwapiszewska, G., Weisel, F. C., Milger, K., Egemnazarov, B., Turowska, A., Fuchs, B., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.035 · Cited by 348
Self-citationDavis, B. N., Hilyard, A. C., Nguyen, P. H., Lagna, G., & Hata, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808788200 · Cited by 327
Cell Death in the Lung: The Apoptosis–Necroptosis Axis
Sauler, M., Bazan, I. S., & Lee, P. J. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114320 · Cited by 326
Mittal, M., Roth, M., König, P., Hofmann, S., Dony, E., Goyal, P., Selbitz, A.-C., Schermuly, R. T., Ghofrani, H. A., Kwapiszewska, G., et al. (2007) · Circulation Research · doi:10.1161/circresaha.107.148015 · Cited by 326
Self-citationPathology of Pulmonary Hypertension
Tuder, R. M., Marecki, J. C., Richter, A., Fijalkowska, I., & Flores, S. (2007) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2006.11.010 · Cited by 324
The Metabolic Theory of Pulmonary Arterial Hypertension
Paulin, R., & Michelakis, E. D. (2014) · Circulation Research · doi:10.1161/circresaha.115.301130 · Cited by 314
Pulmonary arterial hypertension
Montani, D., Günther, S., Dorfmüller, P., Perros, F., Girerd, B., Garcia, G., Jaïs, X., Savale, L., Artaud-Macari, E., Price, L. C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-97 · Cited by 314
Pulmonary Arterial Hypertension
Chin, K. M., & Rubin, L. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.024 · Cited by 309
Weissmann, N., Dietrich, A., Fuchs, B., Kalwa, H., Ay, M., Dumitrascu, R., Olschewski, A., Storch, U., Mederos y Schnitzler, M., Ghofrani, H. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606728103 · Cited by 304
Self-citationPathobiology of Pulmonary Hypertension
Rabinovitch, M. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092033 · Cited by 301
Transforming growth factor β as a therapeutic target in systemic sclerosis
Varga, J., & Pasche, B. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.26 · Cited by 295
Legchenko, E., Chouvarine, P., Borchert, P., Fernandez-Gonzalez, A., Snay, E., Meier, M., Maegel, L., Mitsialis, S. A., Rog-Zielinska, E. A., Kourembanas, S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0303 · Cited by 295
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension
Guignabert, C., Phan, C., Seferian, A., Huertas, A., Tu, L., Thuillet, R., Sattler, C., Le Hiress, M., Tamura, Y., Jutant, E.-M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86249 · Cited by 276
Savai, R., Al-Tamari, H. M., Sedding, D., Kojonazarov, B., Muecke, C., Teske, R., Capecchi, M. R., Weissmann, N., Grimminger, F., Seeger, W., et al. (2014) · Nature Medicine · doi:10.1038/nm.3695 · Cited by 275
Self-citationThe Metabolic Basis of Pulmonary Arterial Hypertension
Sutendra, G., & Michelakis, E. D. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.004 · Cited by 268
Pulmonary hypertension in interstitial lung disease: Fig. 1—
Behr, J., & Ryu, J. H. (2008) · European Respiratory Journal · doi:10.1183/09031936.00171307 · Cited by 263
The Cancer Paradigm of Severe Pulmonary Arterial Hypertension
Rai, P. R., Cool, C. D., King, J. A. C., Stevens, T., Burns, N., Winn, R. A., Kasper, M., & Voelkel, N. F. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1369pp · Cited by 258
Smooth Muscle Enriched Long Noncoding RNA ( SMILR ) Regulates Cell Proliferation
Ballantyne, M. D., Pinel, K., Dakin, R., Vesey, A. T., Diver, L., Mackenzie, R., Garcia, R., Welsh, P., Sattar, N., Hamilton, G., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.021019 · Cited by 223
Role of PDGF in fibrotic diseases and systemic sclerosis
Trojanowska, M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken265 · Cited by 213
Ricard, N., Tu, L., Le Hiress, M., Huertas, A., Phan, C., Thuillet, R., Sattler, C., Fadel, E., Seferian, A., Montani, D., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007469 · Cited by 208
Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis
Heldin, C. ‐., Lennartsson, J., & Westermark, B. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12690 · Cited by 181
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born, E., Lipskaia, L., Breau, M., Houssaini, A., Beaulieu, D., Marcos, E., Pierre, R., Do Cruzeiro, M., Lefevre, M., Derumeaux, G., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.058794 · Cited by 148
CD146-HIF-1α hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension
Luo, Y., Teng, X., Zhang, L., Chen, J., Liu, Z., Chen, X., Zhao, S., Yang, S., Feng, J., & Yan, X. (2019) · Nature Communications · doi:10.1038/s41467-019-11500-6 · Cited by 121
Vascular involvement in systemic sclerosis (scleroderma)
Postlethwaite, Pattanaik, D., & Brown, M. (2011) · Journal of Inflammation Research · doi:10.2147/jir.s18145 · Cited by 119
Pathways in pulmonary arterial hypertension: the future is here
Sitbon, O., & Morrell, N. (2012) · European Respiratory Review · doi:10.1183/09059180.00004812 · Cited by 117
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin‐induced lung injury
Cortijo, J., Iranzo, A., Milara, X., Mata, M., Cerdá‐Nicolás, M., Ruiz‐Saurí, A., Tenor, H., Hatzelmann, A., & Morcillo, E. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00041.x · Cited by 114
Rieg, A. D., Suleiman, S., Anker, C., Verjans, E., Rossaint, R., Uhlig, S., & Martin, C. (2018) · Respiratory Research · doi:10.1186/s12931-018-0829-5 · Cited by 59
“PDGF [1, 2] leading to the introduction of TKIs in the therapy of PH [2, 4, 65].”
BackgroundInfluential
Metadata
- Authors
- Schermuly, R. T.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-10-01
- Volume
- 115
- Issue
- 10
- Pages
- 2811-2821
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2147944062
- Cited by
- 1,058
- References
- 57
- FWCI
- 39.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.